Impact of cumulative LDL cholesterol and other risk factors on coronary artery disease prevalence in patients with familial hypercholesterolaemia.

Competing Interests: Conflict of interest: G.K.H. reports research grants from the Netherlands Organization for Scientific Research (vidi 016.156.445), Cardio Vascular Research Initiative, European Union, and the Klinkerpad fonds; institutional research support from Aegerion, Amgen, AstraZeneca, Eli Lilly, Genzyme, Ionis, Kowa, Pfizer, Regeneron, Roche, Sanofi, and The Medicines Company; speaker’s bureau and consulting fees from Amgen, Aegerion, Sanofi, and Regeneron until April 2019 (fees paid to the academic institution); and part-time employment and stock holder at Novo Nordisk A/S, Denmark, since April 2019. B.A.H. received a research grant from Silence Therapeutics paid to the institution. E.S.G.S. has received ad-board/lecturing fees, paid to the institution, from Amgen, Sanofi, Astra-Zeneca, Esperion, Daiichi Sankyo, Novo Nordisk, Ionis/Akcea, and Amarin. L.F.R. is cofounder of Lipid Tools and reports speaker’s fee from Ultragenyx, Novartis, and Daiichi Sankyo. S.I. reports no disclosures.